(Stroke. 1996;27:1060-1065.)
© 1996 American Heart Association, Inc.
Articles |
Neuroexcitatory Amino Acids and Their Relation to Infarct Size and Neurological Deficit in Ischemic Stroke
From the Department of Neurology, Hospital General de Galicia, Clínico Universitario, Santiago de Compostela; and the Section of Neurology, Hospital Doctor Josep Trueta, Girona (A.D.), Spain.
Correspondence to José Castillo, MD, Department of Neurology, Hospital General de Galicia, Santiago de Compostela, Spain.
Background and Purpose The participation of excitatory amino acids (EAAs) in the pathogenesis of ischemic neuronal lesion has been experimentally demonstrated, but clinical experience is scarce. Our objective was to examine EAA levels during the acute phase of cerebral infarction in relation to infarct size and intensity of neurological deficit.
Methods Using high-performance liquid chromatography, we determined the glutamate, aspartate, taurine, and glycine concentrations in the plasma and cerebrospinal fluid (CSF) of 128 patients with ischemic cerebral infarction confirmed by CT and 43 control subjects. Blood and CSF samples were obtained on admission within the first 24 hours from symptom onset. The severity of the neurological deficit was assessed with the Canadian Stroke Scale immediately after these tests and at 48 hours after inclusion in the study. Infarct volume was determined in a second CT performed between the 4th and 7th day after the patient's inclusion.
Results The concentration of plasmatic glutamate was 121.39±80.89 µmol/L in the control group and 163.71±103.13 µmol/L in the patient group (P=.015); in CSF it was 3.46±1.20 µmol/L in control subjects and 6.55±4.65 µmol/L in patients (P<.0001). The concentration of glycine in plasma was 158.02±32.15 µmol/L in control subjects and 189.37±74.04 µmol/L in patients (P=.007); in CSF it was 6.18±2.28 µmol/L in control subjects and 11.23±6.96 µmol/L in patients (P<.0001). The concentrations of glutamate in plasma and in CSF were significantly higher in patients with large cerebral infarcts and in those with cortical infarcts. Levels of glutamate and glycine in plasma and CSF were significantly higher in patients with a higher degree of neurological deficit.
Conclusions Our results support the excitotoxic activity of glutamate and glycine in patients with cerebral infarction.
Key Words: blood • cerebral infarction • excitatory amino acids • glutamates
This article has been cited by other articles:
 |
|
 |
|
  J. Dawson and M. Walters New and emerging treatments for stroke Br. Med. Bull., November 7, 2006; (2006) ldl011v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Raiteri Functional pharmacology in human brain. Pharmacol. Rev., June 1, 2006; 58(2): 162 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mallolas, O. Hurtado, M. Castellanos, M. Blanco, T. Sobrino, J. Serena, J. Vivancos, J. Castillo, I. Lizasoain, M. A. Moro, et al. A polymorphism in the EAAT2 promoter is associated with higher glutamate concentrations and higher frequency of progressing stroke J. Exp. Med., March 20, 2006; 203(3): 711 - 717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Romera, O. Hurtado, S. H. Botella, I. Lizasoain, A. Cardenas, P. Fernandez-Tome, J. C. Leza, P. Lorenzo, and M. A. Moro In Vitro Ischemic Tolerance Involves Upregulation of Glutamate Transport Partly Mediated by the TACE/ADAM17-Tumor Necrosis Factor-{alpha} Pathway J. Neurosci., February 11, 2004; 24(6): 1350 - 1357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. CURRY Why Have So Many Drugs with Stellar Results in Laboratory Stroke Models Failed in Clinical Trials?: A Theory Based on Allometric Relationships Ann. N.Y. Acad. Sci., May 1, 2003; 993(1): 69 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Chattipakorn and L. L. McMahon Strychnine-Sensitive Glycine Receptors Depress Hyperexcitability in Rat Dentate Gyrus J Neurophysiol, March 1, 2003; 89(3): 1339 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Espey, A. S. Basile, R. K. Heaton, R. J. Ellis, A. Aliprandi, M. Longoni, L. Tremolizzo, and C. Ferrarese Increased glutamate in CSF and plasma of patients with HIV dementia Neurology, May 14, 2002; 58(9): 1439 - 1440. [Full Text] [PDF]
|
|
|
|
|
|
S. C. Chattipakorn and L. L. McMahon Pharmacological Characterization of Glycine-Gated Chloride Currents Recorded in Rat Hippocampal Slices J Neurophysiol, March 1, 2002; 87(3): 1515 - 1525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Castillo, A. Davalos, J. Alvarez-Sabin, J. M. Pumar, R. Leira, Y. Silva, J. Montaner, and C.S. Kase Molecular signatures of brain injury after intracerebral hemorrhage Neurology, February 26, 2002; 58(4): 624 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Serena, R. Leira, J. Castillo, J. M. Pumar, M. Castellanos, and A. Davalos Neurological Deterioration in Acute Lacunar Infarctions : The Role of Excitatory and Inhibitory Neurotransmitters Stroke, May 1, 2001; 32(5): 1154 - 1161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Castillo, R. Rama, and A. Davalos Nitric Oxide-Related Brain Damage in Acute Ischemic Stroke Stroke, April 1, 2000; 31(4): 852 - 857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. O'Kane, I. Martinez-Lopez, M. R. DeJoseph, J. R. Vina, and R. A. Hawkins Na+-dependent Glutamate Transporters (EAAT1, EAAT2, and EAAT3) of the Blood-Brain Barrier. A MECHANISM FOR GLUTAMATE REMOVAL J. Biol. Chem., November 5, 1999; 274(45): 31891 - 31895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. van der Knaap, R. A. Wevers, S. Kure, F. J. M. Gabreels, N. M. Verhoeven, B. van Raaij-Selten, and J. Jaeken Increased Cerebrospinal Fluid Glycine: A Biochemical Marker for a Leukoencephalopathy With Vanishing White Matter J Child Neurol, November 1, 1999; 14(11): 728 - 731. [Abstract] [PDF]
|
|
|
|
 |
|
 W.-J. Lee, R. A. Hawkins, J. R. Vina, and D. R. Peterson Glutamine transport by the blood-brain barrier: a possible mechanism for nitrogen removal Am J Physiol Cell Physiol, April 1, 1998; 274(4): C1101 - C1107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Davalos, J. Castillo, J. Serena, and M. Noya Duration of Glutamate Release After Acute Ischemic Stroke Stroke, April 1, 1997; 28(4): 708 - 710. [Abstract] [Full Text]
|
|
|
|
|
|
M. Fisher Characterizing the Target of Acute Stroke Therapy Stroke, April 1, 1997; 28(4): 866 - 872. [Abstract] [Full Text]
|
|